About ZymoGenetics
ZymoGenetics was established in 1981 in New York, United States, within the biotechnology sector. Focus is placed on protein-based therapies addressing hematology, cancer, and inflammatory conditions. The pipeline encompasses phase two candidates, including PEG-Interferon lambda for hepatitis C virus infection and IL-21 for metastatic melanoma, alongside a preclinical anti-IL-31 monoclonal antibody targeted at atopic dermatitis. Operations emphasize therapeutic development in these medical areas.
- Headquarter New York, United States
- Stage Public
- SectorsHealthcare
- Website zymogenetics.com
- Social LinkedIn
- Acquired by Bristol-Myers Squibb (Sep 2010)
- Latest Funding Round$100M (USD), Debt – Venture
Jun 2008
- InvestorsBristol-Myers Squibb
& 2 more
- Acquired byBristol-Myers Squibb
(Sep 2010)
Funding Insights of ZymoGenetics
- Total Rounds 2
- Last Round Debt – Venture — $100M
- Investors Count 2
All 2 funding rounds of ZymoGenetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2008 | $100M | Debt – Venture | – | – | |
| Oct 2000 | – | Private Equity Round | – | – |
3 investors in total: 3 institutional.
Investors in ZymoGenetics
ZymoGenetics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Bristol-Myers Squibb, Deerfield and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States |
Investor details for ZymoGenetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ZymoGenetics
5 dated milestones of ZymoGenetics across 29 years, from founding to its latest funding, stage changes and deals.
- Founded ZymoGenetics is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Venture, of $100.0M.
- Exit Acquired by Bristol-Myers Squibb.
Web traffic of ZymoGenetics
Websites that share an audience with ZymoGenetics (zymogenetics.com).
Websites whose visitors overlap most with ZymoGenetics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| trimeris.com | 100% | – | – | View details | |
| xencor.com | 100% | 22.2K | #2,563,685 | View details | |
gemacbio.com | gemacbio.com | 100% | – | – | – |
| trophogen.com | 100% | – | – | View details | |
| optimerpharma.com | 100% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for ZymoGenetics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Zymogenetics
Complete news archive for ZymoGenetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ZymoGenetics
10 companies that operate in the same segment as ZymoGenetics (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ZymoGenetics
ZymoGenetics was founded in 1981 and raised its 1st funding round 19 years after it was founded.
ZymoGenetics is headquartered in New York, United States. It is registered at New York, New York, United States.
ZymoGenetics was established in 1981 in New York, United States, within the biotechnology sector. Focus is placed on protein-based therapies addressing hematology, cancer, and inflammatory conditions. The pipeline encompasses phase two candidates, including PEG-Interferon lambda for hepatitis C virus infection and IL-21 for metastatic melanoma, alongside a preclinical anti-IL-31 monoclonal antibody targeted at atopic dermatitis. Operations emphasize therapeutic development in these medical areas.
ZymoGenetics has 3 investors. Key investors include Bristol-Myers Squibb, Deerfield, and Novo Holdings.
Yes. ZymoGenetics was acquired by Bristol-Myers Squibb in September 2010.